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ABSTRACT
The growing number of botulinum neurotoxin type-A (BoNT/A) preparations on the market has resulted in a search for pharmacologi-
cal, clinical and pharmacoeconomic differences. Patients are occasionally switched from one botulinum toxin formulation to another. 
The aim of this paper was to review studies that have made direct comparisons of the three major BoNT/A preparations presen-
tly on the market: ona-, abo- and incobotulinumtoxinA. We also review the single medication Class I pivotal and occasionally 
Class II-IV studies, as well as recommendations and guidelines to show how effective doses have been adopted in well-estab-
lished indications such as blepharospasm, hemifacial spasm, cervical dystonia and adult spasticity. 
Neither direct head-to-head studies nor single medication studies between all preparations allow the formation of universal 
conversion ratios. All preparations should be treated as distinct medications with respect to their summary of product charac-
teristics when used in everyday practice.
Key words: botulinum toxin type-A, cervical dystonia, blepharospasm, spasticity, hemifacial spasm
(Neurol Neurochir Pol 2021; 55 (2): 141–157)
Introduction
Currently, there are three commercially available botu-
linum neurotoxin type-A (BoNT/A) preparations available, 
widely used and licensed in a majority of countries: onabotu-
linumtoxinA (ONA-BoNT/A, Botox); abobotulinumtoxinA 
(ABO-BoNT/A, Dysport); and incobotulinumtoxinA (INCO-
BoNT/A, Xeomin). 
They have similar mechanisms of action. However, their 
chemical formulations, clinical potency, dosing and safety 
profiles are different. This can result in bio- and pharmaco-
economical equivalence problems. The discussion on bio-
equivalence and switching from one to another preparation is 
still ongoing [1, 2]. This discussion will certainly be continued 
in future as new preparations (e.g. daxibotulinumtoxinA, 
prabotulinumtoxinA) are now in clinical trials. 
L E A D I N G  T O P I C
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Table 1. Selected studies on BoNT/A in treatment of blepharospasm and hemifacial spasm (dose ratio comparison between different products)  
Reference Study design Patient characteristics 
and outcome
BoNT/A and dose 
(U)
Muscle injected/  
/injection guide
Efficacy outcome/  
/adverse events
Nussgens et al. 
1997 [9]
Class II study 
DB, prospective, 
crossover design; com-
parison of ONA- and 
ABO-BoNT/A
n = 212 BS  
Duration of effect  
ONA-BoNT/A  
Mean dose 44 U  
ABO-BoNT/A 





ONA-BoNT/A: 17%;  
ABO-BoNT/A: 24%;  
Ptosis (less with ONA- 
-BoNT/A)












Similar duration of effect: 
13.3 +/- 5.9 weeks for 
ABO-BoNT/A, and 11.2 
+/- 5.8 for ONA-BoNT/A. 
Adverse events noted in 
50% of both 
Roggenkamper 
et al. 2006 [14]




of ONA-BoNT/A and 
INCO-BoNT/A
n = 300 BS adjusted mean 
change in JRS, BDI at weeks 
3, 16 
Duration of effect 
ONA -BoNT/A Mean 
dose 40.8 U  
INCO-BoNT/A Mean 




Efficacy, AEs, duration: 
similar for both 
Wabbels et al. 
2011 [16]
Class I, DB, randomised, 
prospective, parallel 
design; comparison 
of ONA-BoNT/A and  
INCO-BoNT/A 
n = 65 BS 
Change in BDI at weeks 4 
and 8;  
Change in JRS;  
Change in patient global 
assessment at week 4 
ONA-BoNT/A: Mean 
dose 29 U/eye; 
INCO-BoNT/A: Mean 




Similar efficacy and dura-





face design;  
comparison of ONA-
BoNT/A and  
INCO-BoNT/A 
n = 48 BS  
4 consecutive treatments  
JRS, BDI score at each visit.  
Likert scale for Orbicularis 
oculi strength at each visit.  
Likert scale for spasm 
severity at each visit.  
Patient preference 
ONA-BoNT/A or  
INCO-BoNT/A  





Similar effects.  
AEs: not available  






n = 19 BS 
n = 91 HFS 
4 consecutive treatments  
Patient assessment 
of treatment efficacy 
(7-point scale comprising 
excellent, very good, good, 
fairly good, fair, poor, or 
negligible) and duration of 
treatment effect (a 4-point 
scale comprising excellent, 
good, a few weeks, or 
short-lived)
ABO -BoNT/A:  
Mean dose 
BS 80 U 
HFS 46 U. 
INCO-BoNT/A: 
Mean dose 
BS 20 U 
HFS 11 U. 
Mean ratio: 4:1  
Orbicularis oculi 
muscle 
Similar duration of effect 
Kollewe et al. 
2015 [20]
Open study n = 288 BS  










ONA-BoNT/A to  
ABO-BoNT/A 
1:2.3 
ONA- BoNT/A to 
INCO-BoNT/A 
1:1.2 






Similar effects and AEs in 
all three
ABO-A — abobotulinumtoxinA; AE — adverse event; BDI — Blepharospasm Disability Index; BDS — Blepharospasm Disability Scale; BoNT — botulinum neurotoxin; CI — confidence interval; DB — dou-
ble-blind; INCO-A — incobotulinumtoxinA; JRS — Jankovic Rating Scale; ONA-A — onabotulinumtoxinA; PBO — placebo; PC — placebo-controlled; U — unit(s) 
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In Part 1 of this discussion, we presented the basic pharma-
cological differences between all three preparations [3]. Here 
in Part 2, the same group of authors provide a summary of 
product characteristics (SPC) and review the available clinical 
studies on major neurological indications (i.e. blepharospasm, 
BS; hemifacial spasm, HFS; cervical dystonia, CD; and upper 
and lower limb spasticity, ULS, LLS in adults), comparing all 
three BoNT/A preparations in terms of their bioequivalence, 
which is understood as clinical effectiveness, dosing and safety. 
Guidelines and recommendations are also included. We have 
prioritised randomised, double-blind studies, those directly 
comparing different preparations of BoNT/A, but where these 
are lacking we have also looked at Class II–IV studies. We 
review also single medication studies to make indirect com-
parisons for the same indication.
Blepharospasm and hemifacial spasm
BoNT/A is considered to be the first line treatment of BS 
and HFS, but only a few studies have been published com-
paring the different preparations. According to SPC, ONA-
BoNT/A and INCO-BoNT/A are injected into the medial 
and lateral orbicularis oculi of the upper lid and the lateral 
orbicularis oculi of the lower lid. The initial recommended 
dose is 1.25–2.5 U at each site, and it should not exceed 
25 U per eye. At subsequent treatment sessions, the dose 
may be increased up to two-fold if the response to the initial 
treatments is considered insufficient. In the management of 
BS, the dose should not exceed 100 U in total every 12 weeks. 
ABO-BoNT/A is injected in an initial dose of 40 U per eye. 
The injection site should be localised into the junction be-
tween the preseptal and orbital parts of both the upper and 
lower orbicularis oculi muscles of each eye 10 U medially and 
10 U into four sites. If the response to initial treatment is inad-
equate, it may be necessary to increase the dose at subsequent 
visits up to 60 U, 80 U or even 120 U. In the management of 
BS and HFS, the total dose should not exceed 120 U per eye 
every 12 weeks [4–6].
We set out the short characteristics of comparative studies 
in Table 1. Single medication studies are shown in Table 2.
ONA-BoNT/A vs. ABO-BoNT/A
The first study comparing different types of BoNT/A was 
published more than 25 years ago. In the 1995 study by Marion 
et al., 111 patients with BS and HFS with a good response 
to ABO-BoNT/A over at least 12 months of treatment were 
switched to ONA-BoNT/A with dose ratio 3:1, obtaining simi-
lar effects [7]. Two other double-blind studies included 300 pa-
tients with both BS and HFS and compared ONA-BoNT/A to 
ABO-BoNT/A. The authors did not observe any difference in 
clinical efficacy of effect duration at a dose ratio of 1:4 [8, 9]. 
Bihari (2005) in a cross-over prospective, open label study in 
a group of 27 patients with BS and nine patients with HFS, 
confirmed the same efficacy of both products at a dose ratio of 
1:4–1:5 [10]. A retrospective study by Marchetti et al. (2005) 
published the results of 114 patients with BS who received 
for at least 12 months ONA-BoNT/A (mean dose 33 ± 12 U) 
before switching to ABO-BoNT/A (mean dose 147 ± 58 U), 
or conversely started with ABO-BoNT/A (mean dose 125 
± 49 U) before switching to ONA-BoNT/A (mean dose 31 ± 10 U) 
with treatment continuing for one year. The ratio of mean dose 
of ONA-BoNT/A and ABO-BoNT/A ranged from a low of 
1:2 up to a high of 1:11 (mean 1:3 to 1:4) [11]. Bentivoglio et 
al. (2012) compared the pairs of treatments with a switch from 
one brand to another (ONA-BoNT/A and ABO-BoNT/A) 
in the same patient (n = 46 with BS and n = 31 with HFS) in 
consecutive sessions with overlapping clinical outcomes, and 
found ratios to be highly variable (range: 1:1.2–13.3). In most 
cases (65%), it was between 1:3 and 1:5 [12].
ONA-BoNT/A vs. INCO-BoNT/A
Dressler et al. (2009) published the results of a prospec-
tive study comparing ONA-BoNT/A to INCO-BoNT/A in 
a group of patients with different disorders. Two hundred and 
sixty-three patients (including 12 with BS and 17 with HFS) 
who had been previously treated with ONA-BoNT/A for at 
least 12 months under stable conditions were converted, in 
a blinded fashion, to INCO-BoNT/A using a 1:1 conversion 
ratio and with other treatment parameters identical. Patients 
with BS received a mean total dose of 85.1 ± 32.6 U ONA- and 
INCO-BoNT/A and patients with HFS received 44.7 ± 19.5 U. 
There were no subjective or objective differences between both 
products with respect to onset latency, maximum duration of 
therapeutic effect, or adverse effects [13]. The same 1:1 ratio 
was confirmed by two other studies [14, 15]. 
Wabbels et al. found that ONA-BoNT/A vs. INCO-
BoNT/A (mean dose 29 U/eye and 27 U/eye respective-
ly) had comparable magnitude and duration of benefit 
(13 weeks). However, a post hoc analysis showed a sig-
nificantly greater number of ONA-BoNT/A treated patients 
reaching a responder threshold of 4 points on the total score 
of disability [14]. Other studies have shown that patients 
with BS and HFS who were treated with INCO-BoNT/A 
had a significantly shorter treatment interval (10.2 weeks 
vs. 13.0 weeks) or required a higher average dose compared 
to ONA-BoNT/A [2, 15, 16].
Similar results were confirmed in the TRUEDOSE Pilot 
Study. The objective was a retrospective evaluation of the dose 
utilisation of ONA-BoNT/A and INCO-BoNT/A in 14 BS 
patients treated over four years. Patients were switched from 
ONA- (mean dose 14.41 U per eye) to INCO-BoNT/A (mean 
dose 17.09 U). For BS, the average annual dose per patient 
year for ONA-BoNT/A was 50.4 ± 50.6 U, and significantly 
lower vs. INCO-BoNT/A with an average dose of 64.01 ± 
53.2 U (p = 0.002). Average total dose ratio (mean dose/year) 
was 1:1.27. The inter-injection intervals were significantly 
longer (16.25 vs. 14.24 weeks) for ONA- than for INCO-
BoNT/A (p = 0.04) [2].
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Table 2. Selected studies on BoNT/A in treatment of blepharospasm and hemifacial spasm (single toxin, indirect comparisons possible only)
References Study design Patients characteristics 
and outcome measures












n = 12 BS            
Fahn scale and patient 
subjective scale 
ONA-BoNT/A 
25 U/eye, if ineffective 
then 50 U/eye 
Orbicularis oculi 
muscle
Improvement, AEs, reported 
but no percentage numbers 
reported 





n = 11 HFS 
Subjective improvement; 
analogue 10-point scale.  
Objective improvement 
(blinded review of 
videotapes made one 
month after each injection) 
assessed with categorical 
10-point scale
ONA-BoNT/A





muscles to inject 
were based on 
clinical exami-
nation
Subjective improvement after 
79% of injections.
Objective improvement after 
84% of injections.
AEs: facial weakness (97%), facial 
bruising (20%), 
diplopia (13%), ptosis (7%)
Girlanda et al.  
1996 [23]
Class II study
comparing two eyes 
of same patient with 
normal saline control 
n = 6 BS








Reduction in blepharospasm 
AEs: not available 
Truong et al. 
2008 [24]
Class II study, 
DB, randomised, paral-
lel group, PC 








Disability improved in dose-re-
lated manner.
AEs: 
ptosis (13-39-58%), blurred 
vision (23-19-42%), diplopia (10-
16-16%) for doses 40-80-120 U  
respectively
Comments:
80 U/eye preferred as efficacious 
and safe. High number of 
withdrawals. 35% of PBO group 
completed study 
Jankovic et al. 
2011 [25]
Class I, DB, randomised, 
prospective, parallel 
design; randomised 2:1 
to INCO-BoNT/A  
vs. PBO 
n = 109 BS
JRS, BDI score at weeks 3, 6 
and end of study. 
Time for need for new 
injection on basis of JRS 
score > 2, up to 20 weeks 
investigator global assess-
ment 







ptosis (18.9%), dry eye (18.9%) 
ABO-A —  abobotulinumtoxinA; AEs — adverse events; BDI  —  Blepharospasm Disability Index; BDS  —  Blepharospasm Disability Scale; BoNT  —  botulinum neurotoxin; CI  —  confidence interval; DB  —  dou-
ble-blind; INCO-A  —  incobotulinumtoxinA; JRS  —  Jankovic Rating Scale; ONA-A  —  onabotulinumtoxinA; PBO  —  placebo; PC  —  placebo-controlled; U  —  unit(s)
ABO-BoNT/A vs. INCO-BoNT/A
Grosset et al. in a retrospective 12-month study assessed 
dose equivalence ratio between ABO-BoNT/A and INCO-
BoNT/A in a group of 257 cases including 19 patients with BS 
and 91 with HFS. Patients were switched from ABO- (mean 
dose for BS 89 U and for HFS 46 U) to INCO-BoNT/A and 
observed for at least one year. Switching from ABO-BoNT/A 
to INCO-BoNT/A at a 4:1 unit ratio resulted in good thera-
peutic effectiveness in terms of treatment efficacy, duration of 
treatment effect, and adverse events profile [17].
ONA-BoNT/A vs. INCO-BoNT/A  
vs. ABO-BoNT-A
Kollewe et al. published the first study comparing the 
efficacy and adverse effects of all three major BoNT/A 
preparations over a treatment time of 11.2 ± 4.1 years. Two 
hundred and eighty-eight patients with BS were included 
and 85% were treated with a stable dose: 128 patients with 
ONA-BoNT/A (mean dose 47 ± 10 U), 84 patients 
with ABO-BoNT/A (mean dose 120 ± 35 U), and 76 pa-
tients with INCO-BoNT/A (mean dose 62 ± 11 U). No patient 
was switched between preparations throughout the observa-
tion period. The Clinical Global Improvement Scale score 
(2.5 ± 0.6) and adverse effects frequency (3%) were similar in 
all compared preparations. ONA-BoNT/A doses were 16.7 % 
lower than INCO-BoNT/A (p < 0.001), and the dose ratio 
between them was calculated as 1:1.2. Dose ratios between 
ONA- and ABO-BoNT/A was 1:2.3; between INCO- and 
ABO-BoNT/A it was 1:2.0. Therapeutic effects started after 
6.1 days and lasted for 10 weeks and were not significantly 
different between all three products [18]. Papers including di-
rect comparisons between preparations are set out in Table 1.
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Conclusions
 — The range of conversion ratios between all three prod-
ucts extracted from all studies was wide: ONA- vs. 
INCO-BoNT/A from 1:1 to 1:1.27, and between ONA- and 
ABO-BoNT/A from 1:3 to 1:5
 — The number of adverse effects is similar in most studies, 
but duration was slightly longer in ABO- vs. ONA- and 
ONA- vs. INCO-BoNT/A
 — Based on a SPC, and having reviewed studies on the 
efficacy and safety of BS and HFS treatment, making 
comparisons between the available preparations remains 
difficult. This is due to the small number of Class I and 
II trials, differing study designs (sometimes with adopted 
conversion rate) and assessment scales used in these stud-
ies (VAS, Jankovic scale, blepharospasm disability scale), 
and differing sites of injections (pretarsal or preseptal 
region). We believe this results in an inability to establish 
a fixed conversion factor
 — Dosing should be based on individual patient need accord-
ing to the recommendation of the SPC for each BoNT/A 
preparation.
Cervical dystonia (CD)
Due to the insufficient effects of oral pharmacological 
treatment of CD, BoNT/A is currently considered to be the 
first line therapy. According to the SPC, it is recommended 
that for ONA-BoNT/A a maximal dose of 200 U should 
be administered initially, and the dose should not exceed 
300 U in subsequent treatment sessions [4]. There is a similar 
recommendation for INCO-BoNT/A [6]. For ABO-BoNT/A, 
the recommended starting dose is 500 U. As treatment is con-
tinued, the doses may be appropriately adjusted according to 
the treatment effects and observed side effects (e.g. dysphagia). 
However, the maximum dose administered must not exceed 
1,000 U [5].
We set out selected comparative (direct comparison) 
studies in Table 3 and single medication studies (indirect 
comparison) in Table 4.
Comparative studies
There is still little data on direct comparisons of individual 
toxin preparations in CD patients. Studies have compared 
mainly ONA- vs. ABO- and INCO-BoNT/A preparations 
and were aimed at comparing the effectiveness or side effects, 
searching for a conversion ratio.
ONA-BoNT/A vs. ABO-BoNT/A
Odergren et al. included 73 patients in a randomised trial 
comparing ONA- and ABO-BoNT/A, who had previously been 
treated with BoNT/A with good results. They adopted a fixed 
1:3 ratio between products and obtained a similar duration, 
number of side effects, and overall Tsui scale improvement [26]. 
A similar approach was applied by Ranoux et al. in 
a crossover study comparing ONA- and ABO-BoNT/A with 
pre-fixed conversion factors of 1:3 and 1:4. The study included 
patients treated successfully at least twice with ONA-BoNT/A. 
Each patient was subjected to three cycles of therapy. ABO- 
-BoNT/A efficacy was significantly higher for both conversion 
ratios (Tsui scale, pain scale), and the effect lasted longer. 
However, in patients receiving ABO-BoNT/A, adverse events 
(mostly dysphagia) were twice as frequent regardless of the 
dose ratio [27]. 
The aim of the study conducted by Marchetti et al. was to 
evaluate the real-world dose utilisation of ONA- and ABO- 
-BoNT/A for CD and BS. They abstracted utilisation data for 
patients who received ABO- before switching to ONA-BoNT/A, 
or conversely. Patients were identified during scheduled clinic 
visits and selected if they met the study criteria, which included 
treatment for at least two consecutive years (at least one year 
with ABO- or ONA-BoNT/A, then switched and maintained 
on one of them for at least another year, adjusting the dose to 
achieve a similar effect). A total of 114 patients were included in 
the assessment. Ratios of mean dose for ABO- to ONA-BoNT/A 
ranged from a low of 2:1 to a high of 11:1. Thirty-one percent 
of patients fell into the ABO- to ONA-BoNT/A ratio group of 
5:1 to less than 6:1; 30% with a ratio of 4:1 to less than 5:1; and 
only 21% was in a range of 3:1 to less than 4:1 [11]. 
A double-blind, randomised crossover trial by Rystedt et 
al. compared ONA-BoNT/A and ABO-BoNT/A in two differ-
ent dose conversion ratios (1:3 and 1:1.7) when diluted to the 
same concentration (100 U/mL). Forty-six patients received 
three different treatments: ONA- in two different doses and 
ABO-BoNT/A as a control treatment. Efficacy was evaluated 
four and 12 weeks after treatment using, among others, To-
ronto Western Spasmodic Torticollis Rating Scale (TWSTRS); 
no differences were observed. At week 12, a statistically sig-
nificant difference in effect between ONA-BoNT/A (1:3) and 
ABO-BoNT/A was noticed, suggesting a shorter duration of 
effect for ONA-BoNT/A. This study showed that the ratio of 
1:3 resulted in suboptimal efficacy of Botox, and indicates that 
the dose conversion ratio between ONA-BoNT/A 100 U/mL 
and ABO-BoNT/A 100 U/mL may be lower than 1:3, but this 
needs to be validated in a larger study [28]. 
In a randomised, double-blind, multicentre, non-infe-
riority, two-period crossover study performed by Yun et al., 
patients were randomly assigned to initial treatment with 
ABO- or ONA-BoNT/A, and they were followed up for 
16 weeks after the injection. After a 4-week washout period, 
they were switched to the other formulation and followed up 
for another 16 weeks. The primary outcome was the change 
in the Tsui scale between the baseline and week 4 after each 
injection. Mean changes in the Tsui scale between baseline and 
4 weeks after each injection tended to favour ONA-BoNT/A; 
however, this was not statistically significant (4.0 ± 3.9 points 
for the ABO- treatment vs. 4.8 ± 4.1 points for ONA-BoNT/A; 
p = 0.091). The mean changes in the Tsui scale, TWSTRS, the 
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Table. 3. Selected studies on BoNT/A in treatment of cervical dystonia (dose ratio comparison between different products) 
Referen-
ces
Study design Patients characteri-
stics and outcome
BoNT/A and dose 
(U)
Muscles injected/  
/injection guide
Efficacy outcome/  
/adverse events
Odergren 
et al. 1998 
[26]
RCT, DB, parallel group, 
prospective multicentre 
study, comparison of 
ONA- and ABO-BoNT/A
n = 73
Patients with a minimum 
of four previous ONA-
-BoNT/A treatments, 
randomised to receive 
either clinically indicated 
dose of ONA-BoNT/A or 
ABO-BoNT/A with fixed 
ratio 1:3
Tsui scores, duration, 
adverse events
ABO-BoNT/A mean 
dose of 477U (range 
240-720) 
ONA-BoNT/A mean 
dose of 152U (range 
70-240) 
Anatomical landmarks, multi-
ple injections within muscles 
allowed
Tsui score, similar effect 
at week 4 
(ABO-BoNT/A, 49%,  
ONA-BoNT/A, 44%)
Similar duration: 
ABO-BoNT/A mean 83.9 
days 
ONA-BoNT/A mean 80.7 
days
Similar number of AEs 
Ranoux  
et al. 2002 
[27]
RCT, DB, three cycles 
crossover study
n = 54
Tsui scores, TWSTRS pain 
scores, duration, adverse 
events
Effective dose of 
ONA-BoNT/A was 
changed to ABO- 
-BoNT/A at fixed 
ratio 1:3 or 1:4
Anatomical landmarks.  All 
injections performed by 
same neurologist blinded to 
treatment and using same 
technique: one single injec-
tion point per muscle, close 
to motor point
Better effect of  
ABO-BoNT/A at 1:3  
and 1:4 ratios 
AEs: higher with both 
ABO-BoNT/A treatments
Dysphagia:
ONA-BoNT/A 3%, ABO- 
-BoNT/A 15.6%, and 17.3% 
for conversion ratios 1:3 
and 1:4, respectively
Marchetti 




tion of ABO-BoNT/A and 
ONA- BoNT/A for CD 
and BS
n = 114 (both for BS 
and CD)
Patients received ABO- 
-BoNT/A or ONA- BoNT/A 
for at least one year 
before and after drug 
crossover
Ratios of mean dose 
for ABO- and ONA- 
-BoNT/A ranged 
from 2:1 to 11:1
Anatomical landmarks, doses 
and muscles injected were 
determined by physician 
based on individual clinical 
presentation and outcome
ABO- vs. ONA-BoNT/A
5:1 to less than 6:1, (31%)
4:1 to less than 5:1, (30%)
3:1 to less than 4:1, (21%)
Benecke 
et al. 2005 
[30]




TWSTRS, pain scores, 
duration, adverse events
Fixed dose conver-
sion ratio 1:1 
Anatomical landmarks; doses 
and muscles injected were 
determined by physician 
based on individual clinical 
presentation
Effect, duration and AEs 
similar for both
Rystedt  
et al. 2015 
[28]
DB, randomised cross-
over, ONA- BoNT/A and 
ABO-BoNT/A in two 
different dose conversion 
ratios (1:3 and 1:1.7)




ratios (1:3 and 1:1.7), 
diluted to same 
concentration (100 
U/mL)
Anatomical landmarks; doses 
and muscles injected were 
determined by physician 
based on individual clinical 
presentation
Similar effect at week 4 
(TWSTRS)
Shorter duration of effect 
for ONA- BoNT/A
AEs: similar






n = 103 
Tsui scores, TWSTRS pain 
scores, adverse events
Fixed dose conver-





Anatomical landmarks; doses 
and muscles injected were 
determined by physician 
based on individual clinical 
presentation
Similar effects and AEs
 
RCT — Randomised Controlled Trial; DB — double-blind; TWSTRS — Toronto Western Spasmodic Torticollis Rating Scale
proportion of improvement in clinical global impression and 
patient global impression, and the incidences of adverse events, 
were not significantly different between the two treatments. 
In conclusion, the study showed no differences between the 
ABO- and ONA-BoNT/A at a conversion rate of 2.5:1 [29]. 
ONA-BoNT/A vs. INCO-BoNT/A
In a study comparing the effectiveness of treatment with 
ONA- vs. INCO- BoNT/A, Benecke et al. included a large 
group of 463 patients [23]. The efficacy and safety of both 
preparations were compared in a 1:1 dose ratio (209 patients 
treated with INCO- and 205 with ONA-BoNT/A) and ob-
served for 16 weeks. Groups did not differ significantly regard-
ing TWSTRS scores, pain intensity, duration of improvement, 
or side effects [30].
Single medication studies
We identified 11 randomised, double-blind studies 
on the treatment of CD with the use of various BoNT/A 
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Table 4. Selected studies on BoNT/A in treatment of cervical dystonia (single toxin with indirect comparisons only possible)





Muscles injected/ injection 
guide
Efficacy outcome/ adverse 
events







Tsui scale, pain scale 
and global assess-
ment at weeks 2, 4 
and 8, AEs
ABO- BoNT/A, 
250, 500,  
1,000 U,  
placebo
Anatomical landmarks, fixed 
muscles: splenius capitis and 
contralateral sternocleidomas-
toid
Significant improvement at week 4 
for both doses





n = 80 
TWSTRS, pain scale 




Study medication administered 
by intramuscular injection into 
two, three, or four clinically in-
dicated neck muscles in a single 
dosing session, with or without 
EMG guidance. Investigator 
determined number of injection 
sites per muscle and dose at 
each site
Significant improvement at weeks 
4, 8, and 12            
Median duration: 18.5 weeks 
AEs: similar, except blurred vision 
(14 vs. 0%) and muscle weakness 
(11 vs 0%) in ABO-BoNT/A vs. place-
bo group, Dysphagia (16 vs. 9%), but 
not significant








TWSTRS total score 
(baseline vs. week 4
AEs 
INCO- BoNT/A   
120 U, 240 U, or 
placebo 
Anatomical landmarks, number 
of injection sites per muscle, 
volume injected into each mus-
cle, and use of EMG guidance 
were determined at discretion of 
investigator
Improvement at week 4      
AEs: dysphagia (2.7% vs. 11.5% 
vs. 24% in placebo, 120 and 240U 
respectively)






CDSS and physician 
GAS at week 6 
ONA-BoNT/A 
95-360 U  
(mean 236 U), 
or placebo
Anatomical landmarks, doses 
and muscles injected were de-
termined by physician based on 
individual clinical presentation 
and previously established 
treatment regimen 
Improvement at week 6
AEs: rhinitis (6.8% and 3.7% in 
double -blind and open period vs. 
0% placebo. Statistically significant   
dysphagia (6.8% vs. 8.4% vs. 3.7% 
placebo in double-blind open peri-
od, not statistically significant)
RCT — Randomised Controlled Trial; TWSTRS — Toronto Western Spasmodic Torticollis Rating Scale; VAS — Visual Analogue Scale; GAS — Global Assessment Scale; CDSS — Cervical Dystonia Severity Scale; 
EMG — electromyography
preparations. All these studies showed that BoNT/A is effec-
tive in CD therapy over a placebo. However, the used doses 
to achieve the effect of improvement were 500–1,000 U of 
ABO-BoNT/A, 95–360 U of ONA-BoNT/A, and 120–240 U of 
INCO-BoNT/A [31–38].
The use of EMG or US guidance vs. no guidance may have 
influenced the amount of BoNT/A needed, but it was not 
controlled for in any of these studies.
Conclusions
 — The treatment of CD is very challenging. Many factors can 
influence outcomes, such as: a proper pattern of CD rec-
ognition, utilising different approaches in terms of muscle 
selection (e.g. adopting Col-Cap concept), and injection 
guidance with EMG or ultrasound [39–42]
 — Reviewing all cited studies, we note various approaches 
from real life practice up to pre-fixed ratios, different 
solutions, various scales used, and timelines 
 — The range of conversion ratios between all three prod-
ucts extracted from all studies is wide (ONA- vs. IN-
CO-BoNT/A 1:1, and between ONA- and ABO-BoNT/A 
from 1:1.7 to 1:5)
 —  Regarding the studies performed, in comparing different 
BoNT/A preparations it is impossible to establish a fixed 
ratio between doses. When switching patients from one 
to another, one must respect the SPC specific recommen-
dations. 
Upper limb spasticity 
Botulinum neurotoxin-A is widely used in clinical prac-
tice for the treatment of this major complication following 
a stroke, affecting 30–40% of patients [43, 44]. Nevertheless, 
to date there have been no guidelines offering a unified dosage 
standard for consecutive muscles and different BoNT/A for-
mulations. All three major formulations recommend different 
muscles and doses in their SPCs. The total dose per treatment 
session varies from 400 U for ONA-, 500 U for INCO-, and 
1,500 U for ABO-BoNT/A [4–6]. Table 5 sets out the muscle 
patterns and doses extracted from SPCs of three products. 
With the aim of finding the possible conversion ratio between 
different BoNT/A products, we analysed the most important 
studies on the treatment of ULS with all three preparations. 
Adhering to the methodology that we have adopted for this 
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Table 5. Product registration recommendations in upper limb spasticity treatment for three major BoNT/A preparations






Flexor carpi radialis 15–50 U 100–200 U 25–100 U
Flexor carpi ulnaris 10–50 U 100–200 U 20–100 U
Flexor digitorum profundus 15–50 U 100–200 U 25–100 U
Flexor digitorum superficialis 15–50 U 100–200 U 25–100 U
Adductor pollicis 20 U 25–50 U 5–30 U
Flexor pollicis longus 20 U 100–200 U 10–50 U
Flexor pollicis brevis / opponens 
pollicis
- - 5–30 U
Brachialis - 200–400 U 25–100 U
Biceps brachii - 200–400 U 50–200 U
Brachio-radialis - 100–200 U 25–100 U
Pronator teres - 100–200 U 25–75 U
Pronator quadratus - - 10–50 U
Triceps brachii (long head) - 150–300 U -
Pectoralis major - 150–300 U 20–200 U
Subscapularis - 150–300 U 15–100 U
Latissimus dorsi - 150–300 U 25–150 U
Deltoideus - - 20–150 U
Teres major - - 20–100 U
Maximal recommended dose per 
treatment session (according to SPCs)
400 U 1,500 U 500 U
paper, we included in our analysis double-blind, randomised, 
placebo-controlled trials evaluating the efficacy and safety of 
various preparations of BoNT/A in the treatment of upper 
limb spasticity (Tab. 6) [45–58]. Almost all studies evaluated 
BoNT/A effectiveness in post-stroke (PS) spasticity, except for 
Gracies et al. [54] which included post-stroke patients as well 
as subjects with post-traumatic brain injury. 
We did not identify studies directly comparing the clinical 
efficacy and safety of all three BoNT/A products. All of them 
compared the BoNT/A preparations versus a placebo. Based 
on studies included in our analysis, direct comparisons of 
the efficacy and tolerability of these three products are im-
possible. Indirect comparisons of the results are also limited 
and inconclusive due to different patient characteristics and 
various treatment and evaluation methods, e.g. injected muscle 
groups, guidance, used scales, or follow-up duration. These 
different approaches can be seen in Table 6 where we set out 
major data from trials.
Conclusions
 — All studies confirm the effectiveness (in terms of reduction 
of muscle tone and in some also in simple functions) and 
safety of the used doses of BoNT/A market products in 
the treatment of ULS for a wide range of maximal doses: 
ONA-BoNT/A: 120–400 U; ABO-BoNT/A: 100–1,000 U; 
and INCO-BoNT/A: 150–400 U
 — The choice of medical preparation and dose of BoNT/A 
should be adapted to individual patient need, but it is 
recommended not to exceed the maximum doses per 
treatment session according to the SPC
 — However, in a few studies higher doses were used safely: 
1,500 U of ABO-, 600 U of ONA- and 800 U of INCO- 
-BoNT/A [59, 60]. Looking at these dosages, it is impos-
sible to translate one result into another using a simple 
conversion ratio. We cannot present the recommended 
conversion ratio. Switching patients from one preparation 
to another should therefore respect the product charac-
teristics recommendations. 
Lower limb spasticity
Product characteristics of ONA-BoNT/A recommend 
the administration of 300-400 U in a single treatment ses-
sion of focal lower limb spasticity (LLS). The total injected 
dose of BoNT/A should be divided among up to six muscles 
(m. gastrocnemius, m. soleus, m. tibialis posterior, m. flexor 
hallucis longus, m. flexor digitorum longus, and m. flexor digi-
torum brevis), whereas SPC of ABO-BoNT/A recommend doses 
of up to 1,500 U with a spread in the distal muscles (m. soleus, 
m. gastrocnemius, m. tibialis posterior, m. flexor digitorum longus, 
m. flexor digitorum brevis, m. flexor hallucis longus, m. flexor hal-
lucis brevis) as well as in the proximal muscles of the lower limb 
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Table 6. Selected studies on BoNT/A in treatment of upper limb spasticity




Muscles injected/  
/njection guide
Efficacy outcome/  
/adverse events








PS – over 3 months 
MAS, PROM, BI, pain sore, 
GAS, physician and patient 
global assessment of benefit








Improvement at week 16 
AEs: in 16 in ABO-BoNT/A group 
and in 20 in placebo group (mainly 
accidental injury, respiratory and 
urinary tract infections)
Brashear  








PS – over 6 months with AS 
scores of at least 3 in the wrist 
and at least 2 in the fingers;
AS for wrist, fingers, thumb; 
DAS in principal target 
domain (limb position, dress-
ing, hygiene, pain), GAS, 
measurement of neutralising 
antibodies, AEs




FCR, FCU, FDS, FDP, 
FPL, ADDP / NA
Improvement up to 12 weeks;
No major AEs 








PS – mean 25.8 months 
from stroke onset (0.9–226.9 
months)
with wrist, elbow, and finger 
flexor spasticity
MAS, physician and patient 
global assessments, pain, FIM 
and SF-36, AEs 
E1: 90 U   
ONA-BoNT/A 
E2: 180 U   
ONA-BoNT/A




BB, FCR, FCU, FDS, 
FDP /
EMG guidance
Dose dependent MAS reduction 
in: wrist and elbow flexors up to 9 
weeks, and in finger flexors up to 
3 weeks. 
No significant changes in pain, FIM 
or SF-36
AEs in 83.1% (54/65) of ONA- 











PS – over 6 months with  
≥ 2 on MAS for at least two 
of elbow, wrist and finger 
flexors;
AQoL, GAS, VAS for pain 
evaluation, HADs, MAS, 
MMAS, Carer Burden Scale, 
Patient Disability Scale, Global 
Assessment of Benefit by 
investigator and patient, AEs
750-1,000 U   
ABO-BoNT/A in first 




BB, BR, B-R, TRIC, FCR, 
FCU, FDS, FDP, FPL/
ADDP/FPB / 
EMG and/or ES guid-
ance
Significant reduction in spasticity 
(MAS), higher GAS scores and great-
er global benefit up to 20 weeks in 
ONA-BoNT/A vs. placebo
No changes in AQoL;
AEs: treatment-related in 5.5% of 










PS – over 6 months with ≥ 2 
AS for wrist and finger flexors;
AS, DAS, Carer Burden 
Scale, Global Assessment of 
Treatment Benefit by investi-
gator, patient and caregiver, 
development of neutralising 
antibodies, AEs
Up to 400 U   





target was flexed 
wrist and clenched 
fist (FCR, FCU, FDS, 
FDP), and additional-
ly as needed: BB, BR, 
B-R, ADDP, OPPP, FPL, 
FPB, PT, PQ /
EMG and/or ES 
guidance
Improvement of ≥ 1 point in AS 
score at 4 weeks, improvement until 
week 12 in principal therapeutic 
target, and in some tasks of Carer 
Burden Scale 
AE in 21 pts (28.8%) in INCO-BoNT/A 
and 20 (26.7%) in placebo group;   









PS over 6 months with focal 
pattern of both wrist and 
fingers, 3 or 4 MAS for wrist 
flexors, and 2+ for finger 
flexors on  
MAS for wrist, finger flexors 
and thumb, DAS, CGI, ADL, 
AEs
E1: 120–150 U   
ONA-BoNT/A 




FCR, FCU, FDP, FDS, 
FPL, ADDP / EMG or 
ES guidance
Reduction of spasticity and im-
provement in ADL in limb position 
and dressing in E2; E2 more effec-
tive than E1 in reduction of wrist 
spasticity;
investigator’s and patient’s CGI 
significantly higher in E2 compared 
to placebo group; 
patient’s CGI significantly higher at 
weeks 1 and 4 in E1 compared to 
placebo group;
AEs: 47% in E2, 38% in E1 and 57% 
in placebo group 
Æ
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Muscles injected/  
/njection guide
Efficacy outcome/  
/adverse events








PS after 3-24 months with 
unilateral ULS
focal spasticity in wrist or 
fingers, ability to initiate wrist 
extension of at least 10° from 
a fully flexed position;
WMFT, MAS, AROM, SIS (qual-
ity of life), AEs
ONA-BoNT/A 300 U 
or
placebo
Wrist and fingers 
flexors / according 
to anatomical land-
marks
Improvement in MAS 
No significant changes in WMFT, 
AROM, SIS;
AEs: one related to study (swelling 
and localised haematoma after 
injections)
Marciniak  








PS – over 6 months with 3 or 4 
MAS for shoulder adductors/
internal rotator and shoulder 
pain;
MAS, PROM, daily pain 
ratings using VAS, DAS for 
dressing, hygiene, pain and 
cosmesis, FIM - upper body 
dressing, hygiene, McGill Pain 






PECM (100-150 U), 
TM (40-60 U) / ac-
cording to anatomi-
cal landmarks
Improvement in MAS, PROM, DAS 
for hygiene and Fugl-Meyer Scale
No significant changes in FIM; 
AEs: none treatment-related








PS after 2-12 weeks with MAS 
≥ 1+ in elbow or wrist joint, 
Asian ethnicity;
MAS, BI, mRS, Functional 
Motor Assessment
Scale scores, PROM, AROM








BB, BR, FCR, FCU, FDP, 
FDS, FPL / NA
Significant improvement in MAS at 
all time points (24 weeks), improve-
ment in PROM and active finger 
movements (hand closed)
at weeks 4, 8, and 12; no significant 
changes in BI, mRS, Functional 
Motor Assessment scores;
AEs: 48 (57%) in ABO-BoNT/A and 
36 (43%) in placebo group








PS or PTBI – over 6 months, 
MAS in the PTMG ≥ 2
PGA of treatment response 
using a 9-point scale, DAS in 
principal target domain (hy-








PTMG among elbow, 
wrist, or finger 
flexors, and into at 
least two additional 
muscle groups from 
elbow, wrist, or finger 
flexors or shoulder 
extensors  
ES guidance
MAS score reduction in PTMG in E1 
and E2 groups; superiority in PGA; 
no significant improvements in DAS;
AEs: treatment related in 2 (2%), 6 
(7%), and 7 (9%) pts in placebo, E1 
and E2 groups, respectively (most 
commonly mild muscle weakness). 
All AEs – mild or moderate








PS – over 3 months with
flexed elbow, flexed wrist, and 
clenched fist with
AS ≥ 2 on at each site and 
a clinical need for a total dose 
of 400 U of INCO-BoNT/A;
AS of PTMG, Investigator’s 
Global Impression of Change 
using a 7-point balanced 
Likert scale; DAS in principal 
target domain (hygiene, 





1 PTMG: flexed elbow 
– 200 U or flexed 
wrist – 150 U  
or clenched fist  
– 100 U and other 
muscle groups - in-
vestigators decided 
dose and number 
of injection sites per 
muscle within prede-
fined ranges 
EMG and/or ES 
guidance
Improvements in PTMG in AS, 
superiority in Investigator’s Global 
Impression of Change, functional 
improvements in DAS;
AEs: 47 of 210 subjects. AE of special 
interest in 7 subjects (3.3%), most 
commonly dry mouth (4 subjects) 








PS – 2–12 weeks with MAS 
≥ 2; 
time between UL injection, 
MAS, UL active motor func-
tion, time to reach re-injection 






commonly – elbow 
flexors) / NA
Increased time to re-injection, pro-
longed MAS improvements
AEs: 23 adverse events in 12 
patients; mostly mild-to-moderate 
intensity 
Table 6 cont. Selected studies on BoNT/A in treatment of upper limb spasticity
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Muscles injected/  
/njection guide
Efficacy outcome/  
/adverse events









PS with MAS scores at least 3 
in elbow and at least 2 in wrist 
or fingers;
MAS for elbow, wrist, fingers, 
thumb. 
DAS in principal target do-
main (limb position, dressing, 
hygiene, pain), CGI
ONA-BoNT/A 400 U  
(240U in forearm 
and 160 U in elbow 
flexors)
or
single treatment of 
ONA-BoNT/A (240 U 
in forearm and 
placebo in elbow 
flexors) 







Forearm MAS reduction in 
ONA-BoNT/A and forearm only 
group; elbow flexors greater MAS 
reduction. 
Improvement in DAS,
Investigator’s CGI – similar in both 
groups








PS after 6 weeks, with spastici-
ty and ARAT grasp score ≤ 2;





B, BB, FDS, FDP, FCU, 
FCR  
ES or US guidance
Spasticity reduction in ONA-BoNT/A 
group with significant difference 
between weeks 2 and 12 (elbow) 
and weeks 2 and 6 (wrist); slower 
development of contracture, PROM 
higher in E group. No differences in 
ARAT between groups
RCT — randomised controlled trial; PS — post stroke; MAS — modified Ashworth scale; PROM — passive range of motion; BI — Barthel Index, Goal Attainment Scaling; BB — biceps brachii; FCR — flexor carpi 
radialis; FCU — flexor carpi ulnaris; FDS — flexor digitorum superficialis; FDP — flexor digitorum profundus; AE — adverse event; AS — Ashworth Scale; DAS — Disability Assessment Scale; FPL — flexor pollicis 
longus; ADDP — adductor pollicis; NA — not applicable; FIM — functional independence measure; SF-36 — 36-Item Short-Form Health Survey; E1/E2/E3 — experimental groups; EMG — electromyography; 
pts — patients; AQoL — Assessment of Quality of Life scale; VAS — visual analogue scale; HADs — Hospital Anxiety and Depression Rating Scale; MMAS — Modified Motor Assessment Scale; BR — brachialis; 
B-R — brachio-radialis; TRIC — triceps; FPB — flexor pollicis brevis; ES — electrostimulation; OPP — opponens pollicis; PT — pronator teres; PQ — pronator quadratus; CGI — Clinical Global Impression; ADL 
— activities of daily living; WMFT — Wolf Motor Function Test; AROM — active range of motion; SIS — Stroke Impact Scale; PECM — pectoralis major; TM — teres major; mRS — modified Rankin Score; PTBI — 
post traumatic brain injury; PGA — Physician Global Assessment; PTMG — primary target muscle group; UL — upper limb; ARAT — Action Research Arm Test; US — ultrasound
(m. rectus femoris, m. hamstrings, m. adductor magnus, m. adduc-
tor longus, m. adductor brevis, m. gracillis, m. gluteus maximus). 
There is no recommendation for treatment of focal lower 
limb spasticity in the INCO-BoNT/A SPC. 
The only study that provides findings on the conversion 
ratio (ABO-BoNT/A vs. ONA-BoNT/A) for lower limb 
muscles was performed in a group of healthy volunteers [61]. 
A double-blind, randomised, dose-escalation study assessed 
the electrophysiological response of extensor digitorum brevis 
muscle after BoNT/A injection. Dose response curves for 
1–20 U of ABO-BoNT/A and ONA-BoNT/A showed an initial 
rapid decrease in compound muscle action potential (CMAP) 
at doses ranging from 1 to 6 U, although this decrease was 
lower at higher concentrations. Statistical modelling predicted 
that, at the lower concentration, a mean decrease in CMAP to 
73% of baseline value would be achieved with 1 U of ONA-
BoNT/A. For a comparable effect, 1.57 U of ABO-BoNT/A 
would be required. The authors concluded that a dose ratio 
equivalence of 3:1, tested in control clinical trials, would be 
within the statistical error limits of the model [61]. 
There are no studies comparing head-to-head the effective-
ness and safety profile of different BoNT/A formulations in the 
treatment of adult LLS. But there have been nine randomised 
controlled trials (RCTs) evaluating the effectiveness of differ-
ent preparations of BoNT/A in reducing ankle plantar-flexor 
spasticity [62–70]. These may indirectly show what doses 
were used to achieve statistically meaningful effects. How-
ever, seeking a conversion ratio based on such a comparison 
is inappropriate. Detailed descriptions of pivotal studies of 
both ONA- and ABO-BoNT/A in LLS are set out in Table 7.
The doses tested were established at the beginning of most 
studies, and ranged from 500 up to 1,500 U of ABO- and up to 
400 U of ONA-BoNT/A. Adverse events in treatment groups 
were usually more frequent when compared to a placebo, but 
either not clinically relevant or not medication-related. In one 
study, in approximately 20% of patients a significant reduction 
of muscle tone was noticed up to week 16 [63].
There has been no RCT evaluating INCO-BoNT/A in the 
treatment of LLS. An open-label study assessed 71 patients with 
stroke-related ankle plantar-flexor muscles spasticity treated 
with a single injection of INCO-BoNT/A at a maximum total 
dose of 180 U for a change in MAS, frequency of daily spasm, 
and passive ankle dorsiflexion grade of motion. A significant 
reduction in MAS and improvement in other evaluated 
parameters at 30 days was reported (MAS t0 = 3.9 ± 0.6; 
t1 = 2.5 ± 1.0; p = 0.00) and also at 90 days (MAS t0 = 3.9 ± 0.6; 
t1 = 3.0 ± 1.0; p = 0.00) of follow-up. During the study, only 
11% of patients experienced treatment-emergent, but revers-
ible, adverse events [71]. 
It is difficult to weigh up the similarities and differences 
between available studies concerning different BoNT/A 
medications efficacy in the treatment of LLS in adults. These 
studies shared no common endpoints except for MAS of the 
ankle plantar flexor muscles [62–70]. All available studies 
confirm a beneficial effect in reducing MAS score in patients 
treated with BoNT/A. The scheme of BoNT/A injection dif-
fered between the studies with hamstrings being injected, if 
needed, in the Wein study [62]. In all studies, except for that 
by Pittock et al. [64], selected muscles were targeted using ES, 
EMG or US guidance. 
Table 6 cont. Selected studies on BoNT/A in treatment of upper limb spasticity
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Table 7. Selected studies on BoNT/A in treatment of spasticity of ankle plantar flexor muscles






Efficacy outcome/ adverse 
events









MAS for ankle plantar 
flexor, 2MWT, step length, 
stepping rate, RMA, PROM 
of ankle, subjective assess-
ment of pain in knee, leg, 
ankle, foot 
3 doses of abo-
BoNT/A:
1st group (59 pts): 
500 U; 
2nd group (60 pts): 
1,000 U; 
3rd group (60 pts): 
1,500 U
GM, GL, SOL; anatom-
ical landmarks
MAS score reduction throughout 
study period in all groups; greatest 
improvements in MAS score in 3rd 
group; 
AEs: 130 adverse events recorded 
by 68 out of 234 pts (10 pts 
receiving abo-BoNT/A considered 
severe AE and related to treatment: 
pharyngitis, dysphagia, headache, 
somnolence, dizziness, pain, asthe-
nia, abnormal gait) 






MAS and MRC of spastic 
foot, gait assessment, 
Achilles tendon clonus, VAS 
for gait function and pain 
3 doses of ONA-
BoNT/A:
1st group (15pts): 
167 U; 
2nd group (15pts): 
322 U; 
3rd group (15pts): 
540 U
GM, GL, TP, SOL; EMG 
guidance
Reduction of MAS score in all 3 
groups;
AEs: in 3rd group (prolonged 
weakness of treated limb, flu-like 
syndrome, oedema of injected 
limb)







MAS for ankle plantar-
flexor muscles, gait pattern, 
speed of gait, CGI
300 U ONA-BoNT/A; 
placebo
SOL, GM, GL, TP; EMG 
or ES guidance
Significant improvement in MAS 
and CGI (investigator).
No significant differences in gait 
patterns and speed;  
AEs: 7 pts (myalgia)








MAS for ankle plantar-flexor 
muscles, comfortable bare-
foot walking speed, PGA
1,000 U and 1,500 U  
of ABO-BoNT/A; 
placebo
SOL, GM, GL; ES 
guidance
Consistent efficacy in MAS for 
1,500 U 
AEs: falls, pain in extremities, mus-
cle weakness







MAS for ankle plantar-
flexor muscles, CGI, GAS, 
pain scale
ONA-BoNT/A 
(≤ 400 U); placebo
SOL, GM, GL, TP, oth-
ers (FDL, FDB, FHL, 
EH, RF)*
EMG and US guid-
ance
Significantly improved MAS, CGI, 
and GAS scores vs. placebo 
AE: 39pts (injection site pain, injec-
tion site mass, muscular weakness) 
*maximum permitted dose in optional muscles, to a total additional dose of ≤ 100 U during double-blind phase; SOL — soleus; GM — gastrocnemius medial head; GL — gastrocnemius lateral head; TP — tibi-
alis posterior; FDL — flexor digitorum longus; FDB — flexor digitorum brevis; FHL — flexor hallucis longus; EH — extensor hallucis; RF — rectus femoris; PGA — physician global assessment; 2MWT — 2-min 
walking test; RMA — Rivermead Motor Assessment; PADFM — passive ankle dorsiflexion grade of motion; SFS — spasm frequency scale; AE — investigator-determined treatment-related adverse events 
The presented studies reported that amounts of ONA- 
-BoNT/A (range 300-400 U), ABO-BoNT/A (500-1,500 U) 
and 180 U of INCO-BoNT/A were effective and safe. 
Conclusions
 — The comparative study was performed in lower limb 
muscles of healthy volunteers without spasticity, using an 
electrophysiological method of assessment
 — It is challenging to establish the comparative poten-
cies and the equivalence ratio between ABO-BoNT/A, 
INCO-BoNT/A, and ONA-BoNT/A in the treatment of 
LLS limb spasticity, as doses were adapted in almost all 
studies and based on diverse protocols, with no head-to-
-head designs.
Recommendations and guidelines 
In 2009, the US Food and Drug Administration (FDA) 
established non-proprietary names for the BoNT/A prepara-
tions manufactured by Allergan (onabotulinumtoxin A), Ipsen 
(abobotulinumtoxin A), and Merz (incobotulinumtoxin A). 
This decision reflected the opinion that individual BoNT/A 
brands should not be treated as interchangeable due to differ-
ent purification methods and differences in the final product 
of purification, different ways of assessing activity, as well as 
different units in which activity is expressed [72, 73]. Non-pro-
prietary names were also intended to prevent possible errors 
resulting from the use of the same abbreviations for BoNT/A 
products supplied to the market by different manufacturers.
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Dystonia 
Practice guidelines for the BoNT/A treatment of move-
ment disorders were published for the first time by the 
American Academy of Neurology (AAN) in 2008 [74]. This 
document summarised the available studies on the use of 
BoNT/A, /B in the treatment of BS, CD, HFS, limb and la-
ryngeal dystonia, tics and essential tremor. 
Botulinum toxin type-A was assigned a level A recom-
mendation only for the treatment of CD. This was based on 
the results of seven Class I studies (two with ONA-BoNT/A, 
two with ABO-BoNT/A, and three with type B toxin). Level 
B recommendation was assigned for the treatment of BS (two 
Class II studies with Botox), focal upper limb dystonia (one 
Class I study with ABO-BoNT/A and three Class II studies 
with ONA-BoNT/A), laryngeal dystonia (one ONA-BoNT/A 
Class I study) and essential tremor (two Class II studies with 
ONA-BoNT/A). 
The guidelines on the diagnosis and treatment of primary 
dystonias published by the European Federation of Neurolog-
ical Societies (EFNS) in 2011 were less detailed, and all mar-
keted formulations of BoNT/A were considered as the same 
class [75]. The main recommendations considered BoNT/A as 
a first-line treatment for primary cranial (excluding oroman-
dibular), writer’s cramp and CD (level A) [75]. 
Updated AAN practice guidelines for the BoNT/A treat-
ment of BS, CD, adult spasticity and headache were published 
in 2016 (76). The authors noted that there are important 
differences from a clinical point of view between BoNT/A 
preparations, including potency and duration of action. 
Therefore, in the updated document, the efficacy and safety 
of each preparation was evaluated separately. This approach 
resulted in a reduction in the level of recommendation in 
individual indications. Only ABO-BoNT/A obtained a level 
A recommendation for treatment of CD (two Class I studies). 
Both ONA-BoNT/A (one Class I and one Class II study) and 
INCO-BoNT/A (one Class I study) were assigned level B. 
Moreover, the AAN noted that the results of one (Class I) 
comparative study showed that ABO- and ONA-BoNT/A 
are probably equally effective in treating CD. ONA-BoNT/A 
(two Class II studies) and INCO-BoNT/A (one Class I study) 
were considered to be probably effective (Level B) in BS, 
and ABO-BoNT/A was assigned a level C recommendation 
(one Class II study) in this indication. According to com-
parative (two Class I and one Class II) studies, ONA- and 
INCO-BoNT/A are equivalent in efficacy in treating BS, 
while ABO- and ONA-BoNT/A are possibly equivalent (one 
Class II study) [76].
Spasticity in adults
The first report of the Therapeutics and Technology 
Assessment Subcommittee of the AAN on the treatment 
of spasticity with BoNT/A was published in 2008 [74]. The 
conclusion was that BoNT/A is effective in the treatment of 
ULS in adults (level A). This was based on six Class I studies 
including ABO-BoNT/A and four Class I studies with the use 
of ONA-BoNT/A. The therapy was also considered effective 
in LLS (two Class I studies of ABO- and one Class I study of 
Ona-BoNT/A). Botulinum toxin injections were found to be 
effective for reducing muscle tone and increasing the range of 
motion in affected limbs, and probably effective in improving 
active function (level B, one Class I study of ABO-BoNT/A). 
There were no specific recommendations regarding the differ-
ences between products [74].
A European Consensus on the use of BoNT/A in spas-
ticity resulting from the collaboration of 28 experts from 
16 countries was published in 2009 [77]. The authors based 
their conclusions on the results of 21 randomised clinical 
trials (12 in upper limbs, seven in lower limbs and two in 
mixed upper and lower limbs) as well as on the results of one 
meta-analysis. At that time, only ONA- and ABO-BoNT/A 
data were available, and the maximum recommended sin-
gle doses for these preparations were 600 U and 1,500 U, 
respectively. 
The main conclusion was that BoNT/A significantly 
reduced muscle tone and improved passive function in adult 
subjects with spasticity. The authors also attempted to take 
a position on the issues that were not answered directly by the 
results of controlled studies in spasticity. The unwanted spread 
of toxin from the site of injection is a potential cause of side 
effects related to weakness of adjacent and distant muscles. 
From a clinical point of view, the low migration potential is 
a desirable feature that reduces the risk of side effects, some-
thing especially important in spasticity where high doses of 
drugs are used. ABO- and ONA-BoNT/A migration potentials 
were not compared in spasticity studies. However, the results 
of studies in hyperhidrosis and CD showed that ONA- ad-
ministration was associated with less migration than in the 
case of ABO-BoNT/A. The contributors to the Consensus 
clearly expressed their negative opinion on the conversion in 
clinical practice of doses of BoNT/A preparations supplied 
by various manufacturers [77]. This was best expressed by 
Aoki et al.: “It is important that clinicians are familiar with 
the characteristics and dosages of each preparation they use, 
and do not try to convert or extrapolate from one preparation 
to another.” [78]. 
The updated 2016 AAN practice guidelines concluded that all 
three commercially available BoNT/A formulations are effective 
in ULS (level A). The data confirmed that they are effective in 
reducing muscle tension and improving passive function. ABO- 
and ONA-BoNT/A were also recommended (level A) for the 
treatment of LLS. In the case of INCO-BoNT/A, data on its effec-
tiveness in lower limb spasticity was considered insufficient [79]. 
Conclusions
 — No published recommendations have suggested any con-
version ratios between dosages of specific BoNT/A formu-
lations. Even so, when suggesting that two preparations 
are equal in terms of efficacy, this means that a significant 
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treatment effect has been achieved in a Class I or II study 
for a specific indication
 — It is impossible to compare the specific doses used and 
translate them into the ratio between them.
Summary
Having reviewed all studies using BoNT/A different 
preparations for CD, BS, HFS and ULS and LLS, despite there 
being a number of direct comparative studies, there is still 
no definitive evidence on clear ratios between preparations. 
We therefore conclude that despite the similar molecular 
mechanisms of different BoNT/A preparations, in terms of 
basic and clinical studies they should be considered to be dis-
tinct medications. All should be used in accordance with their 
individual SPC. The ongoing clinical trials with new (DAXI or 
PRA-BoNT/A) formulations will make this discussion even 
more difficult and complex.
We have not mentioned so far differences in the potency 
of neutralising antibodies (NAB) formation. Preparations may 
differ in terms of this potency, and switching the treatment 
from one to another preparation, as suggested by Hefter et al., 
may be helpful. During the 48-week period of INCO-BoNT/A 
treatment, NAB titres in patients with previously ineffective 
treatment with the use of other preparations decreased in 
32.2%, did not change in 45.2%, and increased in only 22.6% 
of patients. Thus, repeated treatment with a low dose of 
200 U INCO-BoNT/A over 48 weeks provided a beneficial 
clinical long-term effect [80]. This gives rise to a new per-
spective regarding the problem of switching between these 
medications in clinical practice.
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